Advertisement

Diagnosis and Treatment of the Patient with Abnormal Calcium

  • Elizabeth H. HoltEmail author
Chapter

Abstract

The author describes normal physiology of calcium and phosphorus metabolism and the chemistries associated with their pathophysiology in adults. Extensive discussions are presented about abnormalities of body chemistry in the hypercalcemic and hypocalcemic conditions. The clinical signs and symptoms of patients with these abnormalities are highlighted and provide a framework for diagnosing them. Treatment options for these conditions are given with extensive orientation towards medical therapies.

Keywords

Calcium homeostasis Serum calcium levels Cholecalciferol Hydroxylation Vitamin D3 Calcitriol Ionized calcium Calcium-sensing receptor CaSR Bone resorption Calcium resorption Distal nephron Laboratory measurement Hypercalcemia Signs Symptoms Etiology History Phsyical examination Dehydration Polyuria Polydypsia Disorientation Primary hyperparathyroidism Nephrolithiasis Medications Sarcoidosis Multiple endocrine neoplasia Malignanacy Orthostasis Band keratopathy Granulomatous Kyphosis Costovertebral Diagnostic evaluation Plasma protein Multiple myeloma Chronic hepatitis HIV infection Renal function Intact PTH Immunochemiluminometric assay ICMA 25(OH) vitamin D 1,25(OH)2 vitamin D Nephrocalcinosis Alkaline phosphatase Hypercalciuria Electrocardiography QTc interval Atriventricular block DEXA Dual energy X-ray absorptiometry Radiographs Normocalcemia Renal failure Osteitis fibrosa cystica MEN I MEN II Lithium Familial hypocalciuric hypercalcemia Tertiary hyperparathyroidism Intestinal malabsorption Hyperphosphatemia Bicarbonate reabsorption Hypophosphatemia Markers of bone turnover Pheochromocytoma Thyroid cancer PTH-independent hypercalcemia Humoral hypercalcemia of malignancy Local osteolytic hypercalcemia PTHrP B cell lymphomas Tuberculosis Saline hydration Bisphosphonate Pamidronate Zoledronic acid Parathyroidectomy Calcitonin Tachyphylaxix Hemodialysis Immobilization Calcimimetic Cinacalcet Neuromuscular Tremor Muscle spasm Paresthesias Hypoparathyroidism Autoimmune disease Tumor lysis syndrome Transfusion therapy Rhabdomyolysis Shvostek sign Trousseau sign Tetany Seizure Hemodilution Albumin serum Protein malnutrition Nephrotic ­symdrome Hungry bone syndrome Mucocutaneous candidiasis Hypmagnesemia Pseudohypoparathyroidism Calcium infusion Calcium gluconate 

References

  1. 1.
    Brown EM. Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am J Med. 1999;106:238.PubMedCrossRefGoogle Scholar
  2. 2.
    Lippi G, Salvagno GL, Montagnana M, et al. Influence of short-term venous stasis on clinical chemistry testing. Clin Chem Lab Med. 2005;43:869.PubMedCrossRefGoogle Scholar
  3. 3.
    Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343:1863.PubMedCrossRefGoogle Scholar
  4. 4.
    Inzucchi SE. Management of hypercalcemia: diagnostic workup, therapeutic options for hyperparathyroidism and other common causes. Postgrad Med. 2004;115:27.PubMedGoogle Scholar
  5. 5.
    Wermers RA, Khosla S, Atkinson EJ, et al. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965–1992. Ann Intern Med. 1997;126:433.PubMedGoogle Scholar
  6. 6.
    Khan A, Bilezikian J. Primary hyperparathyroidism: pathophysiology and impact on bone. Can Med Assoc J. 2000;163:184.Google Scholar
  7. 7.
    Kebebew E, Hwang J, Reiff E, et al. Predictors of single-gland vs multigland parathyroid disease in primary hyperparathyroidism: a simple and accurate scoring model. Arch Surg. 2006;141:777.PubMedCrossRefGoogle Scholar
  8. 8.
    Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658.PubMedCrossRefGoogle Scholar
  9. 9.
    Brown EM. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol Clin North Am. 2000; 29:503.CrossRefGoogle Scholar
  10. 10.
    Dunbar ME, Wysolmerski JJ, Broadus AE. Parathyroid hormone-related protein: from hypercalcemia of malignancy to developmental regulatory molecule. Am J Med Sci. 1996;312:287.PubMedCrossRefGoogle Scholar
  11. 11.
    Rankin W, Grill V, Martin TJ. Parathyroid hormone-related protein and hypercalcemia. Cancer. 1997;80 Suppl 8:1564.PubMedCrossRefGoogle Scholar
  12. 12.
    Corso A, Ferretti E, Lazzarino M. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology. 2005;10:215.PubMedCrossRefGoogle Scholar
  13. 13.
    Wermers RA, Kearns AE, Jenkins GD, et al. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med. 2007; 120:911.PubMedCrossRefGoogle Scholar
  14. 14.
    Ziegler R. Hypercalcemic crisis. J Am Soc Nephrol. 2001;12 Suppl 17:S3.PubMedGoogle Scholar
  15. 15.
    Zometa (zoledronic acid) prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf.
  16. 16.
    Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249.PubMedCrossRefGoogle Scholar
  17. 17.
    Bilezikian JP, Khan AA, Potts Jr JT. Guidelines for the management of asymptomatic primary ­hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94:335.PubMedCrossRefGoogle Scholar
  18. 18.
    Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319.PubMedCrossRefGoogle Scholar
  19. 19.
    Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135.PubMedCrossRefGoogle Scholar
  20. 20.
    Betterle C, Greggio NA, Volpato M. Clinical review 93: autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 1998;83:1049.PubMedCrossRefGoogle Scholar
  21. 21.
    Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777.PubMedCrossRefGoogle Scholar
  22. 22.
    Meyer C. Scientists probe role of vitamin D: deficiency a significant problem, experts say. JAMA. 2004;292:1416.PubMedCrossRefGoogle Scholar
  23. 23.
    Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18.PubMedGoogle Scholar
  24. 24.
    NIH, Office of Dietary Supplements. Dietary supplement fact sheet: vitamin D. 2009. http://dietary-­supplements.info.nih.gov/factsheets/vitamind.asp. Accessed 25 Nov 2009.

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Section of Endocrinology and Metabolism, Department of Internal MedicineYale University of MedicineNew HavenUSA

Personalised recommendations